Compiled by Magnolia Ark Team | Prostate cancer is a common malignant tumor in men in my country, but due to weak screening awareness, many prostate cancer patients are already in advanced stages when they are diagnosed and cannot be treated with surgical treatment. In recent years, with the emergence of targeted therapy, even patients with advanced prostate cancer can obtain long-term survival after reasonable treatment. Among them, a number of PARP inhibitors have been proven to have outstanding effects in the field of metastatic prostate cancer treatment.
▲Source: medscape
1
Olaparib(Lynparza)
Olaparib (Lynparza) is the world's first PARP inhibitor . Previously, Olaparib has been approved by the United States, Japan, and the European Union for the treatment of metastatic castration-resistant prostate cancer (mCRPC) that has previously received enzalutamide or abiraterone mutations in the treatment of metastatic castration-resistant prostate cancer (mCRPC).
▲Photo source: Reference source [1]
Clinical data show that Olaparib (Lynparza) reduces the risk of disease progression or death by 78%; radiological progression-free survival (rPFS) is longer than 3 times (9.8 months vs 3.0 months); survival is significantly extended (20.1 months vs 14.4 months).
In addition, in February this year, PROpel, a Phase 3 trial of the PARP inhibitor Olaparib combined with abiraterone first-line treatment for metastatic castration-resistant prostate cancer (mCRPC), was released. The study showed that compared with abiraterone alone, Olaparib combined with abiraterone reduced the risk of disease progression by 34%, and the progression-free survival increased by 1.5 times (median PFS: 24.8 months vs 16.6 months) [2].
▲Photo source: Reference source [2]
2
Zejula
Zejula
Zejula
Zejula is an oral, highly selective polyADP ribose polymerase (PARP) inhibitor, which has significant efficacy in tumors with DNA repair defects. In February this year, at the American Society of Clinical Oncology Symposium (ASCO GU), researchers released preliminary data from the Phase 3 MAGNITUDE study of Zejula for metastatic castration-resistant prostate cancer. The results of the
study showed that compared with the control group, the radiological progression-free survival (rPFS) of Zejula combined with Zytiga (abiraterone acetate) and prednisone (prednisone) in the first-line treatment of metastatic castration-resistant prostate cancer significantly improved, and the risk of disease progression or death was reduced by 27% . In addition, the effect of this combination therapy was more significant in in patients with BRCA1/2 gene altered, and the risk of disease progression or death was reduced by 47% [3].
▲Photo source: Reference source[3]
3
Talzenna
Talzenna
Talzenna is an oral polyadenylase diphosphate polymerase (PARP) inhibitor. It has been previously approved by FDA for the treatment of locally advanced or metastatic breast cancer with germline BRCA gene mutation and human epidermal growth factor receptor 2 (HER2) negative.
Recently, the effect of a combination therapy of PARP inhibitor Talzenna (talazoparib) and nonsterol anti-androgen drug Xtandi (enzalutamide) in the treatment of metastatic prostate cancer was disclosed. The results of the TALAPRO-2 phase 3 clinical trial showed that compared with Xtandi alone, patients with metastatic castration-resistant prostate cancer (mCRPC) may prolong the survival of patients regardless of whether the tumors of patients with metastatic castration-resistant prostate cancer (mCRPC) have homologous recombinant repair (HRR) gene mutations, using a combination therapy of Talzenna + Xtandi can prolong the patient's survival [4].
Xtandi is an androgen receptor inhibitor and is the standard therapy for the treatment of mCRPC, non-metastatic castration-resistant prostate cancer, and metastatic castration-sensitive prostate cancer.
▲Photo source: Reference source [4]
At present, with the development of emerging therapies such as targeted therapy, more and more patients with advanced prostate cancer can also obtain good prognosis.In addition to PARP inhibitors, targeted therapies such as Rubraca and Nubeqa have also been approved for the treatment of prostate cancer.
However, not every targeted drug can be applied to all prostate cancer patients. The specific treatment plan requires a comprehensive assessment of the patient's condition by a professional doctor before can be determined.
As a well-known overseas medical service institution in China, Magnolia Ark has in-depth cooperative relationships with more than 100 authoritative hospitals in Japan, the United States and the United Kingdom. It can provide remote consultation and one-stop overseas medical treatment services for patients with advanced prostate cancer, helping patients find ideal treatment plans and significantly improve patients' prognosis. If you want to learn more about prostate cancer treatment or are interested in seeking a better treatment plan, you can contact the editor via private message or comment.
Reference source:
[1]Lynparza approved in the EU for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-approved-in-the-eu-for-prostate-cancer.html
[2]Lynparza plus abiraterone reduced risk of disease progression by 34% vs. standard-of-care in 1st-line metastatic castration-resistant prostate cancer
https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/lynparza-combo-delays-progression-risk-in-prostate-cancer.html
[3]Janssen Presents New Data Demonstrating the Combination of Niraparib and Abiraterone Acetate Plus Prednisone Significantly Improved Radiographic Progression-Free Survival as a First-Line Therapy in Patients with HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer | Johnson & Johnson
https://www.jnj.com/janssen-presents-new-data-demonstrating-the-combination-of-niraparib-and-abiraterone-acetate-plus-prednisone-significantly-improved-ra diographic-progression-free-survival-as-a-first-line-therapy-in-patients-with-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer
[4]Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial | Pfizer
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-topline-results-phase-3-talapro-2
